SELLAS Life Sciences Reports Positive Follow-Up Immune Respo

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , United States , Bruce Mackle , Angelos Stergiou , National Cancer Institute , Life Sciences Reports Positive , Life Sciences Group Inc , Memorial Sloan Kettering Cancer Center , Bristol Myers Squibb , Genfleet Therapeutics Shanghai Inc , Nasdaq , Lifesci Advisors , Survival Data , Completed Phase , Galinpepimuts Combined , Advanced Malignant Pleural , Efficacy Met , Clinical Activity , Increased Survival Observed , Median Overall Survival , Patients Treated , Combination Therapy , Refractory Patients Treated , Overall Survival , Specific Immune Response , Survival Time , Sciences Group , Wilms Tumor , Malignant Pleural Mesothelioma , Genfleet Therapeutics , Annual Report , Sci Advisors ,